News and Events


Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

December 21st, 2018

Licensing rights are worldwide excluding US, Canada, Japan and South America

Read article

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and pal...

December 12th, 2018

Akynzeo® for injection received a permanent J code,  J1454, in the US, by the Centers for Medicare and Medicaid Services  Lugano, Switzerland, Decembe...

Read article

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine i...

December 3rd, 2018

LUGANO, Switzerland and San Diego, USA, December 3, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products...

Read article

Helsinn and Mundipharma China Pharmaceutical announce tha approval of ALOXI®IV b...

December 3rd, 2018

Approval by the National Medical Products Administration (NMPA) brings ALOXI® to a large new patient population ALOXI® is a globally approved  anti-em...

Read article

ONO Submits an Application for Manufacturing and Marketing Approval of Anamoreli...

November 27th, 2018

Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President and Representative Director: Gyo Sagara; “ONO”) announced today that ONO has submitted in Japan ...

Read article



  • 20th March 2019 - 21st March 2019
  • New York
Full event info

CPhI Japan

  • 18th March 2019 - 20th March 2019
  • Tokyo
Full event info

JP Morgan

  • 7th January 2019 - 10th January 2019
  • San Francisco
Full event info